These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37798397)

  • 21. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
    Okam MM; Ebert BL
    Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin.
    Abdulmalik O; Ghatge MS; Musayev FN; Parikh A; Chen Q; Yang J; Nnamani I; Danso-Danquah R; Eseonu DN; Asakura T; Abraham DJ; Venitz J; Safo MK
    Acta Crystallogr D Biol Crystallogr; 2011 Nov; 67(Pt 11):920-8. PubMed ID: 22101818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization.
    Ikuta T; Thatte HS; Tang JX; Mukerji I; Knee K; Bridges KR; Wang S; Montero-Huerta P; Joshi RM; Head CA
    Arch Biochem Biophys; 2011 Jun; 510(1):53-61. PubMed ID: 21457702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
    N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisickling effect of chrysin is associated with modulation of oxygenated and deoxygenated haemoglobin via alteration of functional chemistry and metabolic pathways of human sickle erythrocytes.
    Nwankwo HC; Idowu AA; Muhammad A; Waziri AD; Abubakar YS; Bashir M; Erukainure OL
    Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S108-S124. PubMed ID: 34151613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of the antisickling compound GBT1118 on the permeability of red blood cells from patients with sickle cell anemia.
    Al Balushi H; Dufu K; Rees DC; Brewin JN; Hannemann A; Oksenberg D; Lu DC; Gibson JS
    Physiol Rep; 2019 Mar; 7(6):e14027. PubMed ID: 30916477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin.
    Omar AM; Mahran MA; Ghatge MS; Bamane FH; Ahmed MH; El-Araby ME; Abdulmalik O; Safo MK
    Molecules; 2016 Aug; 21(8):. PubMed ID: 27529207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, Synthesis, and Antisickling Investigation of a Thiazolidine Prodrug of TD-7 That Prolongs the Duration of Action of Antisickling Aromatic Aldehyde.
    Alhashimi RT; Ahmed TA; Alghanem L; Pagare PP; Huang B; Ghatge MS; Omar AM; Abdulmalik O; Zhang Y; Safo MK
    Pharmaceutics; 2023 Oct; 15(11):. PubMed ID: 38004527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling.
    Nakagawa A; Lui FE; Wassaf D; Yefidoff-Freedman R; Casalena D; Palmer MA; Meadows J; Mozzarelli A; Ronda L; Abdulmalik O; Bloch KD; Safo MK; Zapol WM
    ACS Chem Biol; 2014 Oct; 9(10):2318-25. PubMed ID: 25061917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting HbS Polymerization.
    Ferrone FA
    Semin Hematol; 2018 Apr; 55(2):53-59. PubMed ID: 30616807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic screening of the ReFRAME drug repurposing library to discover new drugs for treating sickle cell disease.
    Metaferia B; Cellmer T; Dunkelberger EB; Li Q; Henry ER; Hofrichter J; Staton D; Hsieh MM; Conrey AK; Tisdale JF; Chatterjee AK; Thein SL; Eaton WA
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2210779119. PubMed ID: 36161945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schiff base adducts of hemoglobin. Modifications that inhibit erythrocyte sickling.
    Zaugg RH; Walder JA; Klotz IM
    J Biol Chem; 1977 Dec; 252(23):8542-8. PubMed ID: 925011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding antisickling agents and the sickling process.
    Godwin M; Baysinger M
    Nurs Clin North Am; 1983 Mar; 18(1):207-14. PubMed ID: 6550864
    [No Abstract]   [Full Text] [Related]  

  • 34. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies.
    Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE
    Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent.
    Iyamu EW; Turner EA; Asakura T
    Br J Haematol; 2002 Jul; 118(1):337-43. PubMed ID: 12100171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploration of Structure-Activity Relationship of Aromatic Aldehydes Bearing Pyridinylmethoxy-Methyl Esters as Novel Antisickling Agents.
    Pagare PP; Ghatge MS; Chen Q; Musayev FN; Venitz J; Abdulmalik O; Zhang Y; Safo MK
    J Med Chem; 2020 Dec; 63(23):14724-14739. PubMed ID: 33205981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease.
    Olubiyi OO; Olagunju MO; Strodel B
    Molecules; 2019 Dec; 24(24):. PubMed ID: 31842406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Voxelotor does not inhibit sickle hemoglobin fiber formation upon complete deoxygenation.
    Worth EH; Fugate MK; Ferrone FA
    Biophys J; 2023 Jul; 122(13):2782-2790. PubMed ID: 37270670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients.
    Rab MAE; van Oirschot BA; Bos J; Merkx TH; van Wesel ACW; Abdulmalik O; Safo MK; Versluijs BA; Houwing ME; Cnossen MH; Riedl J; Schutgens REG; Pasterkamp G; Bartels M; van Beers EJ; van Wijk R
    Am J Hematol; 2019 May; 94(5):575-584. PubMed ID: 30784099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.